Velcade Four-Month Review Reflects FDA’s Internal Goal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approval of Millennium’s Velcade in less than four months reflects FDA’s internal goal to approve the multiple myeloma agent before the full six months allotted for the priority review.